close

Robert A. Freedman

Co-Chair, Capital Markets & Public Companies

Partner, Corporate  

San Francisco 650.335.7292

Overview

Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the technology and life sciences industries. He represents issuers and underwriters in public offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting and stock exchange rules and requirements.

Rob co-chairs Fenwick’s capital markets and public companies group, helping clients raise capital, navigate risk and tell a story through filings and disclosures over the long-term. For example, he represented Loxo Oncology in its initial public offering, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public offerings and its $850 million convertible senior notes offering in 2018. The transactions illustrate Rob’s commitment to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019​ program.

Representati​ve Initial Public Offerings

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Dermira
  • Dexcom
  • Goldman Sachs
  • Loxo Oncology
  • Morphic Holding
  • Obalon Therapeutics 
  • Piper Jaffray & Co.
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics ​
  • Sutro Biopharma
  • Upwork

Representati​ve Mergers and Acquisitions

  • Loxo Oncology in its $8B acquisition by Eli Lilly
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Castlight Health in its acquisition of Jiff
  • Corium in its $504M acquisition by Gurnet Point Capital
  • KalVista Pharmaceuticals in its share purchase agreement with Carbylan Therapeutics
  • DexCom in its acquisition of SweetSpot Diabetes Care
  • Zappos.com in its $847M acquisition by Amazon.com
  • Alpha Innotech in its acquisition by Cell Biosciences
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe

Awards and Recognition

  • Best Lawyers named Rob among “The Best Lawyers in America” for his work in corporate law and securities and capital markets law (2020)
  • Chambers USA ranked Rob as a top capital markets lawyer (2019)
  • LMG Life Sciences recognized Rob as a Star (2019)
  • US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
  • The Legal 500 recognized Rob for his capital markets practice (2019, 2018, 2017, 2016)
​​